Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483457 · ClinicalTrials.gov registry record
Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 33
- Enrollment target
NCT00483457: Completed study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00483457 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00483457 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the skin. PURPOSE: This laboratory study is looking at the effects of EGFR inhibitors in the skin of cancer patients.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG enzyme inhibitor therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
What the finished NCT00483457 record still lists
NCT00483457 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00483457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00483457 about?
NCT00483457 is a clinical study titled "Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients". RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the skin. PURPOSE: This laboratory study is looking at the effects of EGFR in...
What is the current status of trial NCT00483457?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00483457?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), enzyme inhibitor therapy (DRUG).
Who is sponsoring clinical trial NCT00483457?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia